Sugi Predict

Sugi Predict / Compounds / SCHEMBL2707620

SCHEMBL2707620

SCHEMBL2707620

CN1CCN(Cc2ccc(C(N)=O)cc2C(F)(F)F)CC1

nearest known ligand 0.66

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.66
▸ KIT P10721 7/20 0.57
▸ DDR1 Q08345 2/20 0.54
▸ BRAF P15056 4/20 0.53
▸ KDM4E B2RXH2 1/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ POLB P06746 1/20 0.52
▸ EGFR P00533 3/20 0.52
▸ SRC P12931 1/20 0.51
▸ ABL1 P00519 3/20 0.51
▸ CSF1R P07333 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31536436 0.94 NR1H2 (0.59) NR1H2KITDDR1BRAFEGFR
SCHEMBL27997931 0.90 NR1H2 (0.60) NR1H2KITDDR1BRAFKDM4E
SCHEMBL3311056 0.90 NR1H2 (0.52) NR1H2KITDDR1ABL1
SCHEMBL16380771 0.89 NR1H2 (0.51) NR1H2KITDDR1BRAFKDM4E
SCHEMBL374704 0.88 NR1H2 (0.64) NR1H2KITDDR1BRAFKDM4E
SCHEMBL2777362 0.88 DDR1 (0.51) NR1H2KITDDR1KDM4EALDH1A1
SCHEMBL27910162 0.87 NR1H2 (0.57) NR1H2KITBRAFEGFRCSF1R
Hydrochloric Acid SCHEMBL3561263 0.87 NR1H2 (0.62) NR1H2KITDDR1BRAFKDM4E
SCHEMBL16380735 0.87 NR1H2 (0.49) NR1H2KITDDR1BRAFKDM4E
SCHEMBL17316205 0.87 NR1H2 (0.62) NR1H2KITDDR1BRAFKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136781-A ROR 1-targeted inhibitor and synthesis method and application thereof 北京大学 2025-06-13 — — CN claimed
CN-119587550-A Application of flumatinib in preparation of medicines for treating pulmonary arterial hypertension 江苏万邦生化医药集团有限责任公司 2025-03-11 — — CN claimed
CN-111072636-B Synthesis method of flumatinib 江苏豪森药业集团有限公司 2022-08-23 — — CN claimed
CN-111763170-B Preparation method of flumatinib intermediate 江苏豪森药业集团有限公司 2022-03-18 — — CN claimed
CN-111072636-A Synthesis method of flumatinib 江苏豪森药业集团有限公司 2020-04-28 — — CN claimed
US-10221181-B2 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2019-03-05 — — US claimed
US-20170327506-A1 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS NERVIANO MEICAL SCIENCES S.r.l. (IT) 2017-11-16 — — US claimed
EP-3218378-A1 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2017-09-20 — — EP claimed
WO-2016075224-A1 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-05-19 — — WO claimed
CN-103435595-A Acetylenic heteroaryl compounds ARIAD PHARMA INC 2013-12-11 — — CN claimed
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS NOVARTIS AG 2011-12-08 — — US claimed
US-20100113467-A1 Organic Compounds NOVARTIS AG 2010-05-06 — — US claimed
US-20100029626-A1 Cyclic sulfones useful as mitochondrial sodium-calcium exchangers NOVARTIS AG (CH) 2010-02-04 — — US claimed
EP-2146964-A2 ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE Novartis Ag (CH) 2010-01-27 — — EP claimed
US-20090030009-A1 Heterobicyclic Carboxamides as Inhibitors for Kinases NOVARTIS AG (CH) 2009-01-29 — — US claimed
EP-1996558-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES Novartis AG (CH) 2008-12-03 — — EP claimed
EP-1996578-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES Novartis AG (CH) 2008-12-03 — — EP claimed
WO-2008125691-A2 ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE NOVARTIS AG (CH) 2008-10-23 — — WO claimed
WO-2008009487-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2008-01-24 — — WO claimed
WO-2007104538-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2007-09-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029626-A1 Cyclic sulfones useful as mitochondrial sodium-calcium exchangers SLC8B1, MCU, GLS NR1H2 3262/4885KIT 2084/4885DDR1 2964/4885
US-20090030009-A1 Heterobicyclic Carboxamides as Inhibitors for Kinases PHKG1, MAP3K20, CDK2 NR1H2 3005/4885KIT 550/4885DDR1 1457/4885
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K19 NR1H2 2047/4885KIT 452/4885DDR1 1991/4885
US-20100113467-A1 Organic Compounds SLCO2A1, SLCO1B1, SLCO2B1 NR1H2 440/4885KIT 2326/4885DDR1 4853/4885
US-20170327506-A1 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS DCK, RET, ADK NR1H2 3987/4885KIT 322/4885DDR1 1022/4885
US-10221181-B2 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors DCK, RET, PRKCA NR1H2 3362/4885KIT 123/4885DDR1 1154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.